Clinical Trial Detail

NCT ID NCT02366143
Title TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel

Bevacizumab + Carboplatin + Nab-paclitaxel

Atezolizumab + Carboplatin + Paclitaxel

Age Groups: adult

No variant requirements are available.